Generate Biomedicines Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Net Income	-222.97	-181.38
Depreciation & Amortization	13.18	15.35
Stock-Based Compensation	20.58	19.47
Other Adjustments	3.21	0.7
Change in Receivables	0.31	-0.21
Changes in Accounts Payable	-2.13	3.5
Changes in Accrued Expenses	17.37	4.37
Changes in Unearned Revenue	-31.89	34.54
Changes in Other Operating Activities	1.73	-14.08
Operating Cash Flow	-200.62	-117.75
Capital Expenditures	-3.51	-3.45
Sale of Property, Plant & Equipment	-	0.01
Purchases of Investments	-164.73	-282.98
Proceeds from Sale of Investments	285.01	228.69
Investing Cash Flow	116.77	-57.73
Long-Term Debt Repaid	-8.16	-11.12
Net Long-Term Debt Issued (Repaid)	-8.16	-11.12
Issuance of Common Stock	1.1	1.13
Net Common Stock Issued (Repurchased)	1.1	1.13
Issuance of Preferred Stock	21.97	96.32
Net Preferred Stock Issued (Repurchased)	21.97	96.32
Other Financing Activities	13.15	5
Financing Cash Flow	28.06	91.33
Net Cash Flow	-55.79	-84.15
Free Cash Flow	-204.13	-121.2
FCF Margin	-640.06%	-592.39%
Free Cash Flow Per Share	-6.19	-3.78
Levered Free Cash Flow	-262.94	-184.67
Unlevered Free Cash Flow	-240.15	-156.48

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q